Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis

NCT00396409 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Asthma

Interventions

DRUG: Depigoid
DRUG: Omalizumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals